• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering

December 9, 2022 By Sean Whooley

Ypsomed Eli LillyYpsomed announced today that Eli Lilly (NYSE:LLY) elected to stop their joint project to enter the U.S. insulin pump market.

In November 2020, the companies entered into a commercialization agreement. The agreement entailed registering and commercializing Ypsomed’s YpsoPump under Lilly’s branding in the U.S. Ypsomed said that, over the past two years, it customized its pump for the U.S. market in preparation for commercialization. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016.

According to a news release, it plans to continue its development program for the U.S. pump. The company said it intends to deepen discussions with other interested parties.

YpsoPump features a prefilled cartridge and a state-of-the-art automated insulin delivery system. The company plans to submit the pump to the FDA in the second half of 2023. It expects commercialization to come with a new partner thereafter.

Burgdorf – Eli Lilly and Co. (NYSE: LLY) decided to fully focus on its successful drug portfolio. Therefore, Lilly elected to stop the joint project with Ypsomed (SIX: YPSN) to enter the U.S. insulin pump market. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner.

“The commercial success of mylife Loop with YpsoPump in Europe demonstrates its high acceptance amongst people with diabetes,” Ypsomed said in the news release.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Eli Lilly, Eli Lilly & Co., Ypsomed

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS